JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on December 13, 2005; DOI: 10.1124/jpet.105.097782


0022-3565/06/3171-97-108$20.00
JPET 317:97-108, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.097782v1
317/1/97    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guo, M.
Right arrow Articles by Scicli, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guo, M.
Right arrow Articles by Scicli, A. G.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

9L Gliosarcoma Cell Proliferation and Tumor Growth in Rats Are Suppressed by N-Hydroxy-N'-(4-butyl-2-methylphenol) Formamidine (HET0016), a Selective Inhibitor of CYP4A

Meng Guo, Richard J. Roman, Joseph D. Fenstermacher, Stephen L. Brown, John R. Falck, Ali S. Arbab, Paul A. Edwards, and A. Guillermo Scicli

Henry Ford Hospital, Detroit, Michigan (M.G., J.D.F., S.L.B., A.S.A., P.A.E.); Medical College of Wisconsin, Milwaukee, Wisconsin (R.J.R.); University of Texas Southwestern Medical Center, Dallas, Texas (J.R.F.); and Henry Ford Hospital and Wayne State University, Detroit, Michigan (A.G.S.)

The present study examined the effects of N-hydroxy-N'-(4-butyl-2 methylphenyl) formamidine (HET0016), a selective inhibitor of the formation of 20-hydroxyeicosatrienoic acid (20-HETE) on the growth of 9L rat gliosarcoma cells in vitro and in vivo. After 48 h of incubation, HET0016 reduced the proliferation of 9L in vitro by 55%, and this was associated with a fall in p42/p44 mitogen-activated protein kinase and stress-activated protein kinase/c-Jun NH2-terminal kinase phosphorylation and increased apoptosis. HET0016 inhibited epidermal growth factor (EGF) and platelet-derived growth factor (PDGF)-induced proliferation and diminished phosphorylation of PDGF receptors. A stable 20-HETE analog increased 9L cell proliferation. In vivo, chronic administration of HET0016 (10 mg/kg/day i.p.) for 2 weeks reduced the volume of 9L tumors by 80%. This was accompanied by a 4-fold reduction in the mitotic index, a 3- to 4-fold increase in the apoptotic index, and a ~50% decrease in vascularization in the tumor. HET0016 treatment increased mean survival time of the animals from 17 to 22 days. Liquid chromatography/mass spectrometry experiments indicated that neither 9L cells grown in vitro nor 9L tumors removed produce 20-HETE when incubated with arachidonic acid. The normal surrounding brain tissue, however, avidly makes 20-HETE, and this activity is selectively inhibited by HET0016. These results suggest that HET0016 may be the prototype of a class of antigrowth compounds that may be efficacious for treating malignant brain tumors. In vivo, it may act in part by inhibiting the formation of 20-HETE by the surrounding tissue. However, the antiproliferative effects of HET0016 on 9L cells in vitro seem unrelated to its ability to inhibit the formation of 20-HETE.


Received for publication October 28, 2005
Accepted December 8, 2005.

Address correspondence to: Dr. Meng Guo, Eye Care Services, Henry Ford Hospital, One Ford Place, 4 D, Detroit, MI 48202-3450. E-mail: mguo1{at}hfhs.org




This article has been cited by other articles:


Home page
Anticancer ResHome page
A. ALEXANIAN, V. A. RUFANOVA, B. MILLER, A. FLASCH, R. J. ROMAN, and A. SOROKIN
Down-regulation of 20-HETE Synthesis and Signaling Inhibits Renal Adenocarcinoma Cell Proliferation and Tumor Growth
Anticancer Res, October 1, 2009; 29(10): 3819 - 3824.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
T. Akbulut, K. R. Regner, R. J. Roman, E. D. Avner, J. R. Falck, and F. Park
20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and c-Src-dependent mechanism
Am J Physiol Renal Physiol, September 1, 2009; 297(3): F662 - F670.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
F. Park, W. E. Sweeney Jr., G. Jia, T. Akbulut, B. Mueller, J. R. Falck, S. Birudaraju, R. J. Roman, and E. D. Avner
Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD
Am J Physiol Renal Physiol, March 1, 2009; 296(3): F575 - F582.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Dhanasekaran, S. Bodiga, S. Gruenloh, Y. Gao, L. Dunn, J. R. Falck, J. N. Buonaccorsi, M. Medhora, and E. R. Jacobs
20-HETE increases survival and decreases apoptosis in pulmonary arteries and pulmonary artery endothelial cells
Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H777 - H786.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
F. Park, W. E. Sweeney, G. Jia, R. J. Roman, and E. D. Avner
20-HETE Mediates Proliferation of Renal Epithelial Cells in Polycystic Kidney Disease
J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1929 - 1939.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.